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This year another 460 000 children were infected with HIV in
sub-Saharan Africa,1 signalling an ongoing failure of
programmes for PMTCT of HIV and the need to revise existing
strategies. Despite initial energetic promotion, in recent years
PMTCT has slipped down the policy agenda and coverage of
these services remains below 10% in most African countries.2
Overall impact of current PMTCT programmes on HIV-free
survival among infants at a population level is unknown but
likely to be low.3,4 In contrast, in many other settings the risk
of transmission is reduced to below 2%, with near-elimination
of paediatric HIV.5-7 In this paper we critique PMTCT strategies
used in Africa and argue they require urgent revision. Under-
utilised opportunities to prevent HIV infection in infants
around childbirth and during breastfeeding are also
highlighted. Interventions during chidbirth and postpartum
would broaden the present antenatal focus of PMTCT
programmes.
BENEFITS OF EARLY KNOWLEDGE OF HIV STATUS
HIV infection will declare itself, commonly with a severe illness 
that has substantial morbidity and mortality. The earlier in HIV
disease that people become aware they are infected, the
greater the benefit of care and treatment interventions.
Further, to prevent transmission of a communicable disease,
infected individuals should be identified as soon as possible
after acquisition. Timely diagnosis of HIV confers considerable
benefits to the individual and the wider community by
facilitating access to care and prevention interventions, and
changes in behaviour that accompany knowledge of status.8,9
Within an enabling policy environment, the role of health
workers is to identify early HIV disease and to maximise the
benefits of knowing one’s status for the infected individual
and their susceptible sexual partners and children. Nowhere is
this more clearly illustrated than in PMTCT programmes.
Each encounter with a woman in maternal and child health
services is an opportunity for the woman to benefit from
knowing her HIV status and to prevent further transmission.
While the advantages for infants in being HIV-free are implicit,
the benefits for women of having an uninfected child need to
be highlighted. When giving pre-test information, health care
workers should ensure that women are adequately informed
of the benefits of PMTCT interventions, and of the emotional
and financial consequences of having an HIV-infected child.
However, many opportunities to benefit from knowing HIV
status are missed with the current emphasis on the individual’s
right to decline testing and the potential harms associated
with testing. The epidemic-long adoption of this approach has,
paradoxically, undermined the individual’s access to
interventions to secure their right to health and that of their
sexual partners and children. After decades of over-mystifying
HIV testing, the pendulum has slowly swung to principles of
public health accompanied by attempts to simplify testing and
counselling procedures.10,11
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Key messages:
• There is a mismatch between the HIV prevention needs of children and the quality and scope of prevention of mother-to-
child transmission (PMTCT) services.
• Although near-elimination of paediatric HIV has taken place in many settings, PMTCT programmes in Africa have little
impact so far.
• Given that it is in the child’s best interests to detect exposure to HIV shortly after birth and to institute preventive
interventions, routine HIV testing may be justified for all infants born to women of unknown HIV status. 
• HIV testing for women at child health and immunisation clinics would enable more women to benefit from knowing their
status and to receive infant feeding counselling and support.
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Additional efforts to ensure that women directly benefit from
PMTCT programmes may increase their acceptability and
uptake. Renaming and remarketing of these programmes may
be necessary. The name PMTCT ignores men’s role in paediatric
HIV infection, and fails to acknowledge that women are more
than just mothers, and require maximum benefits from an HIV
diagnosis, preferably made early in their HIV disease. 
DUAL STANDARDS OF CARE: THE OUTCOME GAP
Initiating antiretroviral therapy (ART) for pregnant women 
helps ensure that benefits of PMTCT programmes accrue to
both women and infants. Though given high priority by PMTCT
guidelines,12 ART for pregnant women with indications for
treatment has been inadequately operationalised. Guidance is
needed on practical aspects of developing well-functioning
linkages between antenatal and ART services. For pregnant
women, accelerating initiation of ART is often necessary to
decrease MTCT risk. Difficulties with timely initiation of ART
during pregnancy are compounded by health-seeking patterns,
with women often first attending antenatal care late in
pregnancy. Measuring CD4 cell counts at the first antenatal
visit appears particularly important in reducing delays.13
So far, efforts to prevent HIV infection in children have focused
on providing short-course ARV regimens for MTCT prophylaxis,
most commonly single-dose NVP (sd-NVP). In several African
countries, studies have recently investigated the role of triple-
ARV regimens used solely for MTCT prophylaxis.14-17 These
regimens are given to women without indications for ART, and
are stopped after childbirth (or after weaning). Such
interventions bridge the gap in outcomes between infants
born to women in Africa (including the South African private
sector18) and those in the USA, Europe, Brazil and other
settings. Long-course triple ARV prophylaxis is the standard of
care in high-income countries (since 1998 in the US19) as well
as in middle-income countries of South America, where more
than 90% of HIV-infected women receive triple-ARV
prophylaxis.5,20 Disparities between infant outcomes illustrate
stark global inequities: in Africa use of sd-NVP entails a risk of
MTCT of about 12%, while elsewhere triple-ARV regimens
reduce transmission to below 2%, with little viral resistance.
Even in the South African private sector, women receive a
standard of care below that provided in the public sector in
countries like Brazil.18
A recent study in Johannesburg showed that risk for MTCT in
women who initiate ART during pregnancy for their own
health is lower than in women who do not have indications for
ART and receive sd-NVP.13 This demonstrates the limitations of
sd-NVP – infants born to women with high CD4 cell counts
had almost a threefold higher risk of HIV infection than infants
born to women with advanced HIV disease (at substantially
higher baseline risk of MTCT).
Several studies are investigating whether ARV drugs, given
either to breastfeeding women or infants, reduce MTCT during
breastfeeding.21 This offers a promising alternative for a
problem that causes tremendous difficulties wherever
replacement feeding is not feasible. ARV drugs have been
shown to reduce MTCT during pregnancy and childbirth in
randomised trials, and in observational studies to reduce HIV
acquisition after sexual or occupational exposure. Evidence
from randomised trials that ARV drugs reduce postpartum
transmission is expected in the next years – about 14 years
after demonstration that ARV drugs reduce antenatal and
intrapartum transmission.
PMTCT ENTRY: THE CHILD’S BEST INTERESTS
In addition to using more effective ARV prophylaxis, to
improve impact of PMTCT programmes, several interventions
around childbirth and during breastfeeding warrant
consideration. These interventions aim to complement and
broaden the current antenatal focus of PMTCT programmes.
Shortly after childbirth, identifying HIV-exposed infants born
to women who have not accessed PMTCT services (either
because these services are unavailable or because they
declined the offer of HIV testing) would enable HIV-exposed
infants to benefit from interventions to reduce their risk of
acquiring HIV. Rapid HIV tests, using whole-blood specimens
from heel sticks, are especially suited to testing newborns for
HIV exposure. Giving ARV post-exposure prophylaxis to
infants born to women who did not receive ARV drugs during
pregnancy or labour has been shown to reduce MTCT in a
randomised trial in Malawi22 and in South Africa.23 If ARV
prophylaxis is delayed more than 2 days, it is unlikely to have
any benefit.24
HIV testing is considered part of essential care around
childbirth for women of unknown HIV status.12 In women who
decline HIV testing, safeguarding the wellbeing of the child
needs to be balanced with protecting the woman’s right to
privacy. The UN Convention on Rights of the Child (CRC)
provides guidance on achieving this balance, stating: ‘In all
actions concerning children, whether undertaken by public or
private social welfare institutions, courts of law administrative
authorities or legislative bodies, the best interests of the child
shall be a primary consideration.’25
South Africa is a signatory of the Convention and in 1995
ratified it, making it legally binding.26 With evidence that post-
exposure prophylaxis for infants is effective, and the high
mortality associated with childhood HIV infection, we argue
that in the best interests of the child, HIV exposure should be
detected, irrespective of the mother’s wishes. Using these
arguments, consistent with the CRC, the overarching priority is
to identify infants exposed to HIV and to deliver interventions
to reduce risk of HIV acquisition. With adoption of this policy,
all infants born to women of unknown HIV status would be
routinely tested for HIV shortly after childbirth. 
Disadvantages of routinely testing all newborn infants may
include: infringing a woman’s right to privacy and deterring
women from accessing labour and delivery services.
Counselling women in these circumstances would be
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challenging, though essential to enable the mother-infant pair
to benefit from safer infant feeding. Concerns about deterring
attendance at health facilities need to be addressed. So far,
inclusion of opt-out HIV testing for adults has not decreased
numbers of people attending services and acceptability of
such testing has been shown to be high in several reports.27-31
While these findings are reassuring, they may not reflect
outcomes of routine testing of newborns. Routine testing of
newborns has occurred in several states in the USA since 1999.
With this policy and opt-out testing for pregnant women, HIV
testing coverage is near universal.32 To our knowledge, no
reports of decreased attendance at health facilities have been
published.33
Essentially, a case could be made that the best interests of the
infant and the infant’s right to preventive health care (article
24 of CRC)25 supersede the woman’s need for autonomy.
Further ethical and legal consideration of this scenario is
necessary. It is surprising that paediatricians have not been
more vociferous advocates for routine testing of newborns,
well within the best interests of those they serve. Similarly,
children with AIDS could argue that by failing to test them for
HIV exposure, the health providers who cared for them around
childbirth neglected to protect them from HIV infection and
did not act in their best interests, as legally obliged. That would
make a fascinating, perhaps winnable, legal test. Schuklenk
and Kleinshmidt go further, arguing for mandatory HIV testing
for women who decide to carry the fetus to term.34 They
contend that women who choose to carry a fetus to term and
choose not to reduce its chances of contracting HIV constitute
harm to others. The authors write: ‘choosing deliberately not
to act to prevent harm when one could have acted without
unreasonably high costs to oneself is comparable to similarly
deliberate actions that actively produce the same amount of
harm’.
POSTPARTUM PMTCT SERVICES
Patient-provider encounters in child health and immunisation
clinics could be used to reduce MTCT. For women who have
not accessed HIV testing during pregnancy or around
childbirth, identifying HIV infection and supporting safer
infant feeding could reduce transmission through
breastfeeding, which accounts for a third to half of HIV
infections in infants. Postpartum testing may be an important
measure while coverage of HIV testing in antenatal clinics is
being improved. Also, women who previously declined testing
may reconsider their decision or form better rapport with the
health worker who offers testing. Women are particularly
vulnerable to HIV acquisition during pregnancy and
postpartum (for reasons of biology and behaviour, such as
lower condom use) and retesting of women who tested
negative during pregnancy may identify recent infection.
During acute HIV infection, risk of transmission to
breastfeeding children35 and sexual partners is high. 
Within child health clinics, postpartum PMTCT services could
be built around HIV testing and counselling; infant feeding
counselling and support; entry to HIV prevention, care and
treatment services; as well as provision of family planning
counselling and contraception. Reducing unintended
pregnancies among HIV-infected women has been promoted
as a key component of PMTCT strategies. Many HIV-infected
women have an unmet need for family planning services,
especially with shortened lactational amenorrhoea due to
replacement feeding or early cessation of breastfeeding. At
any time during the breastfeeding period, identifying HIV
infection in women or HIV exposure in infants enables them to
benefit from infant feeding counselling and support for safer
feeding options.
CONCLUSION
In sum, while HIV infection in infants has effectively been
eliminated in many settings, in Africa the potential for
intervention at each service delivery-point is, so far,
underutilised and of low quality. There is an inequitable
mismatch between the HIV prevention needs of children and
the services provided, necessitating a critical review of
prevailing strategies. Despite the level of funding and
attention available for HIV interventions, by measures such as
coverage, outcomes and equity, PMTCT programmes have
performed worse than syphilis control or ART programmes.
PMTCT has fallen off the HIV bandwagon and needs to climb
back on. For that to occur, stronger bolder national and
international leadership is needed, reenergising the current
approach with innovative strategies based firmly on public-
health principles.
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